Research programme: hepatitis B vaccine and therapy - Dynavax

Drug Profile

Research programme: hepatitis B vaccine and therapy - Dynavax

Latest Information Update: 16 Apr 2008

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 16 Apr 2008 Preclinical development is ongoing
  • 26 Sep 2006 Dynavax and Symphony Dynamo will collaborate on the development of ISS-based therapies for cancer and hepatitis B therapy and hepatitis C therapy
  • 12 Nov 2003 Preclinical trials in Hepatitis B treatment in Asia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top